Journal of Stem Cell Research

Genesis-JSCR-7(3)-96
Volume 7 | Issue 3
Open Access
ISSN: 2582-8797

Beyond the Intervention: Biological Context as a Consideration in Regenerative Medicine

Marina Cordeiro MD[1,2*]
[1]Nova Clinic, Dubai, United Arab Emirates
[2]The Human Code Method-Physician Education Initiative, Dubai, United Arab Emirates

***Corresponding author:** Marina Cordeiro, MD, Nova Clinic, Dubai, United Arab Emirates

Citation: Cordeiro M, Beyond the Intervention: Biological Context as a Consideration in Regenerative Medicine. J Stem Cell Res. 7(3):1-08.

Received: August 17, 2026 | **Published**: August 28, 2026

Abstract

Background: Regenerative medicine has produced some of the most consequential therapeutic advances of the past half-century, from hematopoietic stem-cell transplantation to chimeric antigen receptor (CAR) T-cell therapy, tissue engineering, and gene-replacement therapy. The field's intellectual center of gravity has, understandably, been the intervention itself: the cell, the construct, the vector.

Perspective and Hypothesis: Clinical responses to biologically similar regenerative interventions vary substantially between patients, and much of this variability remains unexplained. Converging evidence from metabolism, mitochondrial biology, immunology, and stem-cell science indicates that tissue repair unfolds within and is influenced by a host biological environment shaped by metabolic state, mitochondrial function, and inflammatory and immune signaling, with further modification by age, genetics, the microbiome, endocrine status, nutrition, exercise, sleep, circadian biology, and environmental exposures. It is hypothesized that systematic characterization of the host biological environment may improve patient stratification, predict therapeutic response, or — if such factors prove modifiable in ways that matter — enhance outcomes of selected regenerative interventions. This hypothesis is unproven; current evidence justifies its investigation, not its adoption.

Conclusions: A staged research agenda is proposed: (1) observational studies testing whether baseline systemic biomarkers predict response to regenerative interventions; (2) prospective validation of candidate predictive biomarkers; and (3) randomized controlled trials testing whether modification of host factors changes regenerative outcomes. The complementarity of intervention-centered and context-aware perspectives — rather than any dichotomy between them — is emphasized throughout.

Keywords

Regenerative medicine; Precision medicine; Systems biology; Inflammaging; Mitochondrial function; Patient stratification; Tissue repair.

Abbreviations

CAR, chimeric antigen receptor; HSCT, hematopoietic stem-cell transplantation (**used in Table 1**); MSC, mesenchymal stromal cell. Trial acronyms (CALERIE, CANTOS) are proper study names and are used as published.

Introduction

Regenerative medicine has been, from its origins, a discipline organized around interventions. The founding vision of tissue engineering was explicitly constructive: to fabricate living substitutes for damaged tissue [1]. That orientation has been vindicated repeatedly. Hematopoietic stem-cell transplantation is a curative, guideline-embedded cellular therapy with more than half a century of accumulated clinical experience [2]. CAR-T cells have transformed the treatment of refractory B-cell malignancies [3,4]. Induced pluripotent stem cells reshaped the field's cell-sourcing horizon [5], and single-dose gene-replacement therapy has altered the natural history of spinal muscular atrophy [6]. These achievements are not the backdrop to this Perspective; they are its premise.

Yet a persistent clinical observation deserves more systematic attention than it typically receives: biologically similar patients, receiving similar interventions for similar indications, often respond differently. Some of this variability reflects disease heterogeneity and technical factors. Some of it, however, may reflect the biological environment into which the intervention is delivered. The idea that host context matters is not new — it is central to systems medicine [7], P4 medicine [8], precision medicine [9], and geroscience [10]. What remains underdeveloped is the specific, clinically actionable question this Perspective proposes: whether systematic characterization of the host environment can improve patient selection, response prediction, or outcomes in regenerative medicine specifically. This article examines the evidence for that possibility, calibrates its current strength honestly, and outlines a research agenda capable of testing it.

Current State of Regenerative Medicine

The contemporary regenerative-medicine portfolio spans cell therapies, tissue engineering, orthobiologics, and gene therapy. Its successes are substantial and, in several domains, definitive: allogeneic and autologous hematopoietic transplantation [2], CAR-T therapy with durable remissions in relapsed B-cell leukemia [3,4], and approved gene-replacement therapy [6] collectively demonstrate that intervention-centered regenerative medicine can cure. These examples matter because they establish what rigorous development pathways in this field look like.

Other domains remain promising but unresolved. Mesenchymal stromal cell (MSC) therapy has generated hundreds of trials but inconsistent efficacy, with donor variability, product heterogeneity, and notably — recipient biology among the proposed explanations [11]. Platelet-rich plasma and related orthobiologics show heterogeneous, frequently low-quality evidence [12]. Meanwhile, a large direct-to-consumer market sells unproven 'regenerative' procedures [13], underscoring the obligation of academic writing in this field to calibrate claims carefully. Across both the successes and the disappointments, one pattern recurs: response variability that the intervention alone does not explain. It is this pattern that motivates a closer look at the host.

It is worth asking what separates the field's unambiguous successes from its unresolved domains. The successes share three features: a molecularly defined therapeutic target, a measurable and clinically meaningful endpoint, and a staged development pathway that earned each expansion of use. They also share a fourth, less-discussed feature: in each case the host environment is actively managed as part of the therapy. Hematopoietic transplantation is preceded by conditioning regimens that deliberately remodel the recipient's marrow and immune environment [2], and CAR-T protocols routinely employ lymphodepletion before cell infusion [3]. In other words, the most successful cellular therapies in medicine already treat the host context as a therapeutic variable — albeit for immunological reasons specific to those settings. The question this Perspective raises is whether an analogous, evidence-based attention to host biology metabolic, mitochondrial, and inflammatory could benefit regenerative applications in which the host environment is currently treated as background rather than as a variable.

Biological Context

Metabolic state

Tissue repair is an energetically demanding, anabolic program, and the systemic metabolic state constrains it. Metabolic flexibility — the capacity to switch between fuel sources in response to demand — is impaired in obesity and insulin resistance [14], and the mechanistic architecture of insulin resistance reaches into essentially every tissue relevant to repair [15]. Chronic overnutrition also produces 'metaflammation', a low-grade inflammatory state that links metabolic dysfunction to the immune environment discussed below [16]. Human evidence that systemic metabolism is modifiable at scale exists: in the CALERIE randomized trial, two years of caloric restriction in non-obese adults was feasible and improved cardiometabolic risk markers [17]. Whether such metabolic modification alters the response to any regenerative intervention has, to my knowledge, not been rigorously tested — which is precisely the point: the question is answerable, and unanswered.

Mitochondrial function

Mitochondria supply the bioenergetic substrate of regeneration and, increasingly clearly, its signals. Mitochondrial decline is a recognized feature of aging tissue [18]; mitochondrial metabolites and reactive oxygen species participate in cell-fate decisions [19]; and mitochondrial quality-control pathways maintain the organelle pool on which progenitor function depends [20]. In aged mice, restoring NAD+ availability improved muscle and neural stem-cell function and modestly extended lifespan [21] — direct preclinical evidence that a mitochondria-targeted systemic factor can alter regenerative capacity. This finding is murine, and human efficacy is unproven; it is cited here as rationale for investigation, not as clinical guidance.

Inflammatory and immune environment

Repair is an immunologically choreographed process. With age, many individuals develop 'inflammaging'- a chronic, low-grade, systemic inflammatory state [22] associated with cardiovascular disease, frailty, and multimorbidity [23]. At the tissue level, macrophage phenotype can determine whether injury resolves toward regeneration or fibrosis [24], and systemic chronic inflammation is increasingly viewed as a shared driver of chronic disease across the lifespan [25]. Two implications follow. First, an intervention delivered into a pro-inflammatory host may encounter a repair environment biased toward fibrosis rather than

DOI: https://doi.org/10.52793/JSCR.2026.7(3)-96

regeneration — a mechanistically grounded but clinically unproven inference. Second, host inflammation is druggable with consequences for hard outcomes: in the CANTOS trial, IL-1β inhibition reduced cardiovascular events independent of lipid lowering [26]. CANTOS was not a regenerative-medicine trial, and its relevance here is proof-of-principle only: a systemic host factor, once considered background biology, proved to be a modifiable determinant of outcome.

Regenerative response

The capacity of a tissue to respond to any regenerative stimulus depends on its stem-cell compartment and the niche that sustains it. Niche composition governs hematopoietic stem-cell behavior [27], and the extracellular matrix is an active regulator — not a passive scaffold — of progenitor fate [28]. Most strikingly, heterochronic parabiosis experiments show that the systemic environment itself can rejuvenate or impair progenitor function: aged progenitors recover regenerative capacity when exposed to a young circulation [29], and young plasma improves synaptic plasticity and cognition in aged mice [30]. These are among the most direct experimental demonstrations that host context shapes regenerative capacity — and they are entirely preclinical. The hallmarks-of-aging framework [31,32], together with genetic evidence that clearing senescent cells delays tissue dysfunction in mice [33], provides a coherent biological vocabulary for these observations without yet providing clinical proof.

Biological modifiers

Age, genetics, the microbiome, endocrine status, nutrition, exercise, sleep, circadian biology, and environmental exposures are best understood as lateral modifiers of the three domains above rather than as sequential stages (**Figure 1**). Several have human evidence within or adjacent to regenerative settings: gut microbiota composition tracks with immune reconstitution after hematopoietic transplantation [34]; exercise carries therapeutic evidence across dozens of chronic diseases [35]; sleep loss is measurably pro-inflammatory [36]; and circadian disruption impairs metabolic homeostasis [37]. None of these observations demonstrates that modifying the factor improves regenerative outcomes; collectively, they establish that the host environment is neither fixed nor unmeasurable.



Figure 1: Biological context and regenerative response. Regenerative interventions act within a host biological environment shaped by metabolic state, mitochondrial function, and the inflammatory/immune

milieu. Biological modifiers (dashed boxes) — age, genetics, microbiome, sleep, nutrition, exercise, endocrine status, and environmental exposures — influence this context laterally rather than as sequential stages. Whether systematic characterization of this context improves patient stratification or outcomes of regenerative interventions is an open research question. Per the journal's requirements, Figure 1 is also supplied as a separate high-resolution image file.

Proposed perspective

The hypothesis of this article can now be stated precisely. In selected regenerative interventions, characterization of the host biological environment — metabolic, mitochondrial, and immune-inflammatory — may (i) identify patients unlikely to respond, (ii) predict the magnitude or durability of response, or (iii) reveal modifiable factors whose optimization improves outcomes. Current evidence does not prove any of these three propositions. What current evidence does provide is biological plausibility from multiple independent domains, causal demonstrations in animal models, and human precedents showing that systemic host factors are measurable, modifiable, and — at least outside regenerative medicine — consequential. That combination justifies investigation. It does not justify practice change, and this distinction should govern how clinicians communicate with patients today.

Evidence calibration

The evidence underlying this Perspective is calibrated by level of certainty in (**Table 1**). The calibration distinguishes what is established (that intervention-centered regenerative medicine can be curative), what is supported but incomplete (that host systemic factors are measurable, modifiable, and linked to major outcomes), what is hypothesis-generating (that the host environment shapes regenerative capacity), and what remains unknown (whether characterizing or optimizing host context improves outcomes of regenerative interventions in humans).

Level	Description	Evidence	Clinical implications
Established	Intervention-centered regenerative medicine can be curative	HSCT [2]; CAR-T registration trial data [3,4]; approved gene therapy [6]	Standard of care in defined indications
Supported but incomplete	Host systemic factors (metabolic, inflammatory) are measurable, modifiable, and linked to major outcomes	CALERIE RCT [17]; CANTOS RCT [26]; inflammaging epidemiology [23,25]	Justifies measuring host context in research settings; not yet actionable for regenerative patient selection
Hypothesis-generating	Host environment shapes regenerative capacity	Heterochronic parabiosis [29,30]; NAD+ repletion in mice [21]; senescent-cell clearance [33]; MSC recipient-variability signals [11]	Motivates the research agenda; no clinical action supported
Unknown	Whether characterizing or optimizing host context improves outcomes of regenerative interventions in humans	No adequately powered human trials identified	The open question this Perspective proposes to test

Table 1: Calibration of the evidence underlying this Perspective, by level of certainty.

DOI: https://doi.org/10.52793/JSCR.2026.7(3)-96

HSCT, hematopoietic stem-cell transplantation; CAR-T, chimeric antigen receptor T-cell therapy; MSC, mesenchymal stromal cell; RCT, randomized controlled trial. Bracketed numbers refer to the reference list. Per the journal's requirements, (**Table 1**) is also supplied as a separate cell-based Microsoft Word file.

Challenges and Limitations

Several obstacles stand between this hypothesis and clinical utility, and they should be stated as plainly as the hypothesis itself. There is no standardized biomarker panel for 'host regenerative context'; candidate markers span metabolic, inflammatory, and mitochondrial read-outs with different assay maturity. Multi-omics profiling introduces substantial technical and biological variability, and reproducibility across laboratories remains a genuine constraint. Causal inference is difficult: host factors correlate with age, disease severity, and behavior, and observational associations with outcome will require careful design — and ultimately randomization — to interpret. Trial design is demanding, since stratified and biomarker-guided questions multiply arms and sample sizes; adaptive designs offer a partial remedy [38]. Finally, cost, regulatory complexity, and implementation burden are nontrivial, and any stratification strategy risks widening healthcare inequity if access to profiling is unevenly distributed. A research agenda that ignores these constraints would repeat, in a new vocabulary, the overpromising this field can least afford [13].

Future research agenda

A three-phase strategy could test the hypothesis efficiently and honestly. Phase 1 — prediction: embed standardized baseline systemic profiling (glycemic and lipid indices, inflammatory markers, body composition, and selected mitochondrial or omics read-outs where feasible) into ongoing and future trials and registries of regenerative interventions, and test whether baseline host biology predicts response. This phase requires no change to the interventions themselves. Phase 2 — validation: candidate predictive biomarkers emerging from Phase 1 should be validated prospectively, with pre-registered thresholds and analysis plans, in independent cohorts. Phase 3 — modification: only if validated predictors emerge should randomized controlled trials test whether modifying the relevant host factors (for example, structured metabolic, exercise, sleep, or anti-inflammatory optimization before or alongside an intervention) changes regenerative outcomes — ideally using adaptive designs to manage the combinatorial space [38]. The staged translation of senolytic therapy — from genetic proof-of-concept in mice [33] to small first-in-human pilots with explicit feasibility and target-engagement endpoints [39,40] — offers a sober template: early, small, transparent, and endpoint-disciplined. To be clear, the trials proposed here do not yet exist; that is the gap this agenda is designed to close.

Conclusion

Regenerative medicine's interventions are among modern medicine's genuine triumphs, and nothing in this Perspective argues otherwise. The argument is narrower and, I believe, more useful: the next meaningful gain may not require another intervention at all. Perhaps the next frontier in regenerative medicine is not another therapy, but an answer to a question every clinician in this field has encountered -why biologically similar patients respond so differently to the regenerative interventions we already have. The host biological environment is a scientifically grounded, measurable, and testable place to look.

DOI: https://doi.org/10.52793/JSCR.2026.7(3)-96

Whether it is also a clinically consequential one is exactly what the proposed research agenda can determine.

Declarations

Ethics statement: Not applicable. This Perspective article contains no original human or animal research and no identifiable patient data.

Competing interests: M.C. is the founder of Nova Clinic (Dubai, United Arab Emirates) and clinical lead of The Human Code Method physician education initiative. No commercial product is discussed in this article. No other competing interests are declared.

Funding: This work received no external funding. No study sponsor had any role in the conception, writing, or decision to submit this article for publication.

Author contributions: M.C. conceived the article, performed the literature review, wrote the manuscript, prepared the figure and table, and approved the final version. M.C. is the sole author and guarantor of this work.

Acknowledgements: Artificial-intelligence-based tools were used to assist with literature organization and editorial drafting support under the author's direction; the author reviewed, verified, and takes full responsibility for all content, interpretations, and conclusions.

References

1. Langer R, Vacanti JP. (1993) Tissue engineering. Science. 260(5110):920-6.
2. Copelan EA. (2006) Hematopoietic stem-cell transplantation. N Engl J Med. 354(17):1813-26.
3. June CH, Sadelain M. (2018) Chimeric antigen receptor therapy. N Engl J Med. 379(1):64-73.
4. Maude SL, Laetsch TW, Buechner J. (2018) Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 378(5):439-48.
5. Takahashi K, Yamanaka S. (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 126(4):663-76.
6. Mendell JR, Al-Zaidy S, Shell R. (2017) Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 377(18):1713-22.
7. Auffray C, Chen Z, Hood L. (2009) Systems medicine: the future of medical genomics and healthcare. Genome Med. 1(1):2.
8. Hood L, Friend SH. (2011) Predictive, personalized, preventive, participatory (P4) cancer medicine. Nat Rev Clin Oncol. 8(3):184-7.
9. Collins FS, Varmus H. (2015) A new initiative on precision medicine. N Engl J Med. 372(9):793-5.
10. Kennedy BK, Berger SL, Brunet A. (2014) Geroscience: linking aging to chronic disease. Cell. 159(4):709-13.
11. Galipeau J, Sensébé L. (2018) Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell. 22(6):824-33.
12. Moraes VY, Lenza M, Tamaoki MJ, Faloppa F, Belloti JC. (2014) Platelet-rich therapies for musculoskeletal soft tissue injuries. Cochrane Database Syst Rev. 2014(4):CD010071.
13. Turner L, Knoepfler P. (2016) Selling stem cells in the USA: assessing the direct-to-consumer industry. Cell Stem Cell.19(2):154-7.
14. Goodpaster BH, Sparks LM. (2017) Metabolic flexibility in health and disease. Cell Metab. 25(5):1027-36.
15. Petersen MC, Shulman GI. (2018) Mechanisms of insulin action and insulin resistance. Physiol Rev. 98(4):2133-23.
16. Hotamisligil GS. (2017) Inflammation, metaflammation and immunometabolic disorders. Nature.

542(7640):177-85.
17. Ravussin E, Redman LM, Rochon J. (2015) A 2-year randomized controlled trial of human caloric restriction: feasibility and effects on predictors of health span and longevity. J Gerontol A Biol Sci Med Sci. 70(9):1097-104.
18. Sun N, Youle RJ, Finkel T. (2016) The mitochondrial basis of aging. Mol Cell. 61(5):654-66.
19. Chandel NS. (2014) Mitochondria as signaling organelles. BMC Biol. 12:34.
20. Pickles S, Vigié P, Youle RJ. (2018) Mitophagy and quality control mechanisms in mitochondrial maintenance. Curr Biol. 28(4):R170-85.
21. Zhang H, Ryu D, Wu Y. (2016) NAD+ repletion improves mitochondrial and stem cell function and enhances life span in mice. Science. 352(6292):1436-43.
22. Franceschi C, Bonafè M, Valensin S. (2000) Inflamm-aging: an evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 908:244-54.
23. Ferrucci L, Fabbri E. (2018) Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nat Rev Cardiol. 15(9):505-22.
24. Wynn TA, Vannella KM. (2016) Macrophages in tissue repair, regeneration, and fibrosis. Immunity. 44(3):450-62.
25. Furman D, Campisi J, Verdin E. (2019) Chronic inflammation in the etiology of disease across the life span. Nat Med. 25(12):1822-32.
26. Ridker PM, Everett BM, Thuren T. (2017) Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 377(12):1119-31.
27. Morrison SJ, Scadden DT. (2014) The bone marrow niche for haematopoietic stem cells. Nature. 505(7483):327-34.
28. Gattazzo F, Urciuolo A, Bonaldo P. (2014) Extracellular matrix: a dynamic microenvironment for stem cell niche. Biochim Biophys Acta. 1840(8):2506-19.
29. Conboy IM, Conboy MJ, Wagers AJ, Girma ER, Weissman IL, et al. (2005) Rejuvenation of aged progenitor cells by exposure to a young systemic environment. Nature. 433(7027):760-4.
30. Villeda SA, Plambeck KE, Middeldorp J. (2014) Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice. Nat Med. 20(6):659-63.
31. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. (2017) The hallmarks of aging. Cell. 153(6):1194-217.
32. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. (2023) Hallmarks of aging: an expanding universe. Cell. 186(2):243-78.
33. Baker DJ, Wijshake T, Tchkonia T. (2011) Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature. 479(7372):232-6.
34. Schluter J, Peled JU, Taylor BP. (2020) The gut microbiota is associated with immune cell dynamics in humans. Nature. 588(7837):303-7.
35. Pedersen BK, Saltin B. (2015) Exercise as medicine — evidence for prescribing exercise as therapy in 26 different chronic diseases. Scand J Med Sci Sports. 25(3):1-72.
36. Besedovsky L, Lange T, Haack M. (2019) The sleep-immune crosstalk in health and disease. Physiol Rev. 99(3):1325-80.
37. Panda S. (2016) Circadian physiology of metabolism. Science. 354(6315):1008-15.
38. Pallmann P, Bedding AW, Choodari-Oskooei B. (2018) Adaptive designs in clinical trials: why use them, and how to run and report them. BMC Med. 16(1):29.
39. Justice JN, Nambiar AM, Tchkonia T. (2019) Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study. EBioMedicine. 40:554-63.
40. Hickson LJ, Langhi Prata LGP, Bobart SA. (2019) Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of dasatinib plus quercetin in individuals with diabetic kidney disease. EBioMedicine. 47:446-56.